CN Patent

CN106535896B — 蛋白激酶抑制剂在制备治疗纤维化疾病的药物中的用途

Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2019-06-21 · 7y expired

What this patent protects

蛋白激酶抑制剂6‑(4‑((1‑氨基环丙基)甲氧基)‑1,2‑二氢呋喃并[3,2‑f]喹啉‑9‑基氧基)‑N‑甲基‑1‑萘甲酰胺或5‑(2‑二乙胺基‑乙基)‑2‑(5‑氟‑2‑氧代‑1,2‑二氢‑吲哚‑3‑亚基‑甲基)‑3‑甲基‑1,5,6,7‑四氢‑吡咯[3,2‑c]吡啶‑4‑酮，或者它们的可药用盐中的一种或几种在制备治疗纤维化疾病的药物中的用途。

USPTO Abstract

蛋白激酶抑制剂6‑(4‑((1‑氨基环丙基)甲氧基)‑1,2‑二氢呋喃并[3,2‑f]喹啉‑9‑基氧基)‑N‑甲基‑1‑萘甲酰胺或5‑(2‑二乙胺基‑乙基)‑2‑(5‑氟‑2‑氧代‑1,2‑二氢‑吲哚‑3‑亚基‑甲基)‑3‑甲基‑1,5,6,7‑四氢‑吡咯[3,2‑c]吡啶‑4‑酮，或者它们的可药用盐中的一种或几种在制备治疗纤维化疾病的药物中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN106535896B
Jurisdiction
CN
Classification
—
Expires
2019-06-21
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Hengrui Medicine Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.